Conditionally Active Anti-Epcam Antibodies, Antibody Fragments, Their Immunoconjugates and Uses Thereof

BioAtla Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 2 of these applications claim priority to application PCT/US2020/037096, filed Jun 10, 2020. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

Patent	Title	Holder	Status	Expires	Time remaining	Confidence
US 11,851,499	Conditionally Active Anti-Epcam Antibodies, Antibody Fragments, Their Immunoconjugates and Uses Thereof BioAtla, Inc. In force Ends no later than Jun 10, 2040 · Medium confidence	BioAtla, Inc.	In force	Ends no later than Jun 10, 2040	Ends no later than Jun 10, 2040	Medium confidence
US 12,427,347	Conditionally Active Anti-Epcam Antibodies, Antibody Fragments, Their Immunoconjugates and Uses Thereof BioAtla, Inc. In force Term ends Jun 10, 2040 · Low confidence	BioAtla, Inc.	In force	Term ends Jun 10, 2040	Term ends Jun 10, 2040	Low confidence
Application 19/317,515	Conditionally Active Anti-Epcam Antibodies, Antibody Fragments, Their Immunoconjugates and Uses Thereof BioAtla, Inc. Pending Not granted	BioAtla, Inc.	Pending	Not granted	not computed

3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

2 of these are in force and held by BioAtla Inc..

Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.